Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid Tumor

1 Mar 2019

Abstract excerpt

Atypical teratoid/rhabdoid tumor (AT/RT), which harbors SMARCB1 mutation and exhibits a characteristic histology of rhabdoid cells, has a poor prognosis because of the lack of effective treatments. Here, we establish human SMARCB1-deficient pluripotent stem cells (hPSCs). SMARCB1-deficient hPSC-derived neural progenitor-like cells (NPLCs) efficiently give rise to brain tumors when transplanted into the mouse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Genomics and Chromatin Dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30840885
DOI: 10.1016/j.celrep.2019.02.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human Pluripotent Stem Cell-Derived Tumor Model Uncovers the Embryonic Stem Cell Signature as a Key Driver in Atypical Teratoid/Rhabdoid TumorPMID 30840885Read ↗

Development and epigenetic regulation of Atypical teratoid/rhabdoid tumors in the context of cell-of-origin and halted cell differentiationSemantic proximity Read ↗

Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumorsSemantic proximity Read ↗

Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.Semantic proximity Read ↗

Atypical Teratoid Rhabdoid Tumour : From Tumours to TherapiesSemantic proximity Read ↗

Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.Semantic proximity Read ↗

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.Semantic proximity Read ↗

Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilitiesSemantic proximity Read ↗

AT-21INTEGRATED (EPI)GENOMIC ANALYSES IDENTIFY SUB-GROUP SPECIFIC THERAPEUTIC TARGETS IN CNS RHABDOID TUMORSSemantic proximity Read ↗

Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous.Semantic proximity Read ↗

Inhibition of MYC attenuates tumor cell self‐renewal and promotes senescence in SMARCB1‐deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivoSemantic proximity Read ↗

Recurrent atypical teratoid/rhabdoid tumors (AT/RT) reveal discrete features of progression on histology, epigenetics, copy number profiling, and transcriptomicsSemantic proximity Read ↗

Clinicopathologic comparison of familial versus sporadic atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.